Evidence map›Paper›PMID 39830160›Full record

ArticleJournal of hepatocellular carcinoma2025

Fully Covered Stent-TIPS for Advanced HCC Patients with Portal Vein Tumor Thrombus-Related Severe Symptomatic Portal Hypertension.

Zechuan Liu, Tianshi Lyu, Jinming Yang, Yong Xie, Siyuan Fan, Li Song, Yinghua Zou, Jian Wang

Abstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. The Systemic Immune-Inflammation Index Predicts Portal Vein Tumor Thrombosis and Informs a Clinical Nomogram in HBV-Related Hepatocellular Carcinoma.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zechuan Liu *Department of Interventional and Vascular Surgery, Peking University First Hospital, Beijing, People's Republic of China.ORCID 0000-0002-4673-6318
Tianshi Lyu *Department of Interventional and Vascular Surgery, Peking University First Hospital, Beijing, People's Republic of China.
Jinming YangDepartment of Vascular Interventional, Aerospace Central Hospital, Beijing, People's Republic of China.
Yong XieDepartment of Interventional and Vascular Surgery, Peking University First Hospital, Beijing, People's Republic of China.ORCID 0000-0002-6589-7854
Siyuan FanDepartment of Interventional and Vascular Surgery, Peking University First Hospital, Beijing, People's Republic of China.
Li SongDepartment of Interventional and Vascular Surgery, Peking University First Hospital, Beijing, People's Republic of China.
Yinghua ZouDepartment of Interventional and Vascular Surgery, Peking University First Hospital, Beijing, People's Republic of China.
Jian WangDepartment of Interventional and Vascular Surgery, Peking University First Hospital, Beijing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Portal vein tumor thrombus (PVTT)-related severe symptomatic portal hypertension (SPH) leads to a poor prognosis in patients with advanced hepatocellular carcinoma (HCC). Traditional transjugular intrahepatic portosystemic shunt (TIPS) using covered plus bare stent can effectively relieve SPH, however, the bare segment is susceptible to obstruction due to PVTT invasion. This study aimed to evaluate the safety and efficacy of fully covered stent-TIPS (FCS-TIPS) for treatment of PVTT-related SPH in advanced HCC patients. Patients and Methods: This retrospective study enrolled 25 patients with advanced HCC who underwent FCS-TIPS for PVTT-related severe SPH from June 2018 to January 2024. The evaluated outcomes included overall survival (OS), technical success rate, reduction in portal venous pressure gradient (PPG), stent patency rate, SPH control rate, liver function and complications. Results: The technical success rate was 100% without perioperative deaths or severe procedure-related adverse events. The average PPG decreased by 13.4±4.6 mmHg. The overall symptom control rate of SPH was 96.0%. Variceal bleeding, ascites/hydrothorax, and enteropathy control rates were 100%, 95.0%, and 100%, respectively. Liver function showed mild improvement one month after TIPS. One patient (4.0%) experienced overt hepatic encephalopathy (OHE) and three (12.0%) patients developed shunt dysfunction during the follow-up period. None of the patients experienced shunt-induced extrahepatic metastasis. The median OS was 6.0 months and the cumulative survival rates at 3, 6, 12 months were 80.0%, 52.0% and 21.3%. Conclusion: FCS-TIPS is safe and effective for treating PVTT-related severe SPH and can serve as a bridging therapy for advanced HCC.

Indexed as

fully covered stenthepatocellular carcinomaportal vein tumor thrombussymptomatic portal hypertensiontransjugular intrahepatic portosystemic shunt

Identifiers

PMID39830160
PMCPMC11742244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.